Gain Therapeutics (GANX) to Release Earnings on Tuesday

Gain Therapeutics (NASDAQ:GANX) is expected to post its quarterly earnings results before the market opens on Tuesday, March 25th. Analysts expect Gain Therapeutics to post earnings of ($0.19) per share for the quarter.

Gain Therapeutics Stock Performance

Shares of GANX stock opened at $2.34 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 2.99. Gain Therapeutics has a one year low of $0.89 and a one year high of $4.10. The company’s 50-day simple moving average is $2.23 and its 200-day simple moving average is $2.03. The stock has a market capitalization of $62.07 million, a price-to-earnings ratio of -2.13 and a beta of 0.14.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Roth Capital upgraded shares of Gain Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a research note on Monday, March 17th. Roth Mkm restated a “buy” rating and issued a $7.00 price target on shares of Gain Therapeutics in a research note on Tuesday, December 24th. Finally, Scotiabank initiated coverage on shares of Gain Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 price target on the stock. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $8.20.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.